Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
复制标题
DOI：
10.1186/1471-2407-11-177
复制
发表时间：
2011-05-18
期刊：
影响因子：
3.8
通讯作者：
Shen L
中科院分区：
文献类型：
--
作者：
Gao J;Lu M;Yu JW;Li YY;Shen L
评估胸苷磷酸化酶和β-微管蛋白III在接受卡培他滨联合紫杉醇一线治疗的中国晚期胃癌患者临床结局中的作用。方法回顾性收集2003年7月至2008年12月北京肿瘤医院收治的33例接受卡培他滨联合紫杉醇治疗的晚期胃癌患者（实验组1）和18例接受卡培他滨联合顺铂治疗的晚期胃癌患者（对照组2）的临床资料和治疗前肿瘤活检标本，采用免疫组化方法检测胸苷磷酸化酶和β-微管蛋白III的表达。通过统计学分析确定生物标志物的表达与反应或生存之间的关系。51例患者的中位年龄为57岁（范围27-75岁），其中男性34例，女性17例，有效率、中位无进展生存期和总生存期分别为43.1%、120天和265天。在队列1中，β-tubulin III阳性患者（n = 22）和阴性患者（n = 11）的缓解率、中位无进展生存期和总生存期分别为36.4%/72.7%（阳性vs阴性，P = 0.049），86天/237天（P = 0.046）和201 d/388 d（P = 0.029）;有效率（87.5% vs 14.3%，P = 0.01）和中位无进展生存期胸苷磷酸化酶阳性且β-微管蛋白III阴性患者（n = 8）的平均寿命（251天vs 84天，P = 0.003）也明显高于胸苷磷酸化酶阴性且β-微管蛋白III阳性患者（n = 7）。在队列2（n = 18）中，β-微管蛋白III表达与缓解或生存率之间无相关性。胸苷磷酸化酶阳性和β-微管蛋白III阴性可预测卡培他滨联合紫杉醇化疗的疗效和预后。应在大样本中进行进一步的前瞻性评价，以证实这些初步结果。
To assess the role of Thymidine Phosphorylase and β-tubulin III in clinical outcome of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. The clinical data and tumor biopsies prior treatment from 33 advanced gastric cancer patients receiving capecitabine plus paclitaxel (cohort 1, experimental group) and 18 patients receiving capecitabine plus cisplatin (cohort 2, control group) in Beijing Cancer Hospital from July 2003 to December 2008 were retrospectively collected and analyzed for Thymidine Phosphorylase and β-tubulin III expressions by immunohistochemistry. The relationships between expressions of biomarkers and response or survival were determined by statistical analysis. The median age of 51 patients was 57 years (range, 27-75) with male 34 and female 17, and the response rate, median progression-free survival and overall survival were 43.1%, 120d and 265d. Among cohort 1, the response rate, median progression-free survival and overall survival in β-tubulin III positive (n = 22) and negative patients (n = 11) were 36.4%/72.7% (positive vs negative, P = 0.049), 86d/237d (P = 0.046) and 201d/388d (P = 0.029), respectively; the response rate (87.5% vs 14.3%, P = 0.01) and median progression-free survival (251d vs 84d, P = 0.003) in Thymidine Phosphorylase positive & β-tubulin III negative patients (n = 8) were also significantly higher than those in Thymidine Phosphorylase negative & β-tubulin III positive patients (n = 7). There was no correlation between β-tubulin III expression and response or survival among cohort 2 (n = 18). In Chinese advanced gastric cancer, Thymidine Phosphorylase positive & β-tubulin III negative might predict response and prognosis to capecitabine plus paclitaxel chemotherapy. Further prospective evaluation in large samples should be performed to confirm these preliminary findings.
登录
查看更多内容
影响因子：
3.4
作者：
Ishitsuka, H
通讯作者：
Ishitsuka, H
影响因子：
45.3
作者：
Heinrich, MC;Corless, CL;Fletcher, JA
通讯作者：
Fletcher, JA
影响因子：
45.3
作者：
Meropol, Neal J.;Gold, Philip J.;Schwarting, Roland
通讯作者：
Schwarting, Roland
影响因子：
11.2
作者：
Mozzetti, Simona;Iantomasi, Raffaella;Ferlini, Cristiano
通讯作者：
Ferlini, Cristiano
影响因子：
50.5
作者：
Andreetta, C.;Puppin, C.;Puglisi, F.
通讯作者：
Puglisi, F.